Analyst Price Targets — LINE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 17, 2026 11:40 am | — | UBS | $45.00 | $44.27 | TheFly | Lineage price target raised to $45 from $35 at UBS |
| June 18, 2026 11:52 am | — | Scotiabank | $45.00 | $41.53 | TheFly | Lineage price target raised to $45 from $42 at Scotiabank |
| June 17, 2026 11:42 am | Michael Lewis | Truist Financial | $46.00 | $42.83 | TheFly | Lineage price target raised to $46 from $44 at Truist |
| June 8, 2026 12:07 pm | — | Evercore ISI | $44.00 | $42.69 | TheFly | Lineage price target raised to $44 from $41 at Evercore ISI |
| June 2, 2026 11:36 am | — | Morgan Stanley | $47.00 | $44.03 | TheFly | Lineage price target raised to $47 from $39 at Morgan Stanley |
| May 15, 2026 8:50 am | — | Barclays | $35.00 | $39.40 | TheFly | Lineage price target raised to $35 from $34 at Barclays |
| May 7, 2026 11:55 am | Steve Sakwa | Evercore ISI | $41.00 | $37.81 | TheFly | Lineage price target raised to $41 from $38 at Evercore ISI |
| April 27, 2026 8:50 am | — | Barclays | $34.00 | $37.14 | TheFly | Lineage downgraded to Underweight from Equal Weight at Barclays |
| January 13, 2026 12:19 pm | — | Barclays | $38.00 | $37.19 | TheFly | Lineage downgraded to Equal Weight from Overweight at Barclays |
| January 9, 2026 3:33 pm | — | Scotiabank | $39.00 | $36.44 | TheFly | Lineage price target raised to $39 from $37 at Scotiabank |
Latest News for LINE
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Value Line, Inc. (NASDAQ – VALU ) announced today that its Board of Directors declared on July 17, 2026 a quarterly cash dividend of $0.35 per common share, payable on August 11, 2026, to stockholders of record on July 27, 2026. The Company has 9,383,573 shares of common stock outstanding as of July 17, 2026.
Lineage Cell Therapeutics NYSEAMERICAN: LCTX used a conference call to outline its manufacturing strategy and development plans for COR1, a wholly owned preclinical cell transplant program being developed as a potential treatment for corneal endothelial disease.
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions, today provided an update on COR1, the Company's allogeneic corneal endothelial cell (CEnC) transplant program, in preclinical development for the…
Lineage remains a Buy, offering a margin of safety and re-rating potential despite near-term macro and operational headwinds. Q1 saw AFFO per share decline 9.3% to $0.78, but guidance for Adj. EBITDA ($1.25–$1.3B) and AFFO per share ($2.75–$3.00) were maintained. LINE's cost reduction plan and automation investments target $110M annualized EBITDA improvement in 3–5 years, supporting long-term upside.
MIDDLEBURY, Ind., July 08, 2026 (GLOBE NEWSWIRE) -- Grand Design RV, the fast-growing innovator of travel trailers, 5th wheels and motorized RVs, today announced the launch of the all-new Lineage series E, expanding its award-winning motorized portfolio with a new Class C motorhome designed to deliver premium comfort, practical functionality and confidence on the road. Built on the dependable Ford® E-450 chassis,…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.